Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Cash (2016 - 2025)

Historic Change in Cash for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$80.7 million.

  • Abeona Therapeutics' Change in Cash fell 33128.88% to -$80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 50975.12%. This contributed to the annual value of $8.9 million for FY2024, which is 337031.25% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Change in Cash stood at -$80.7 million, which was down 33128.88% from $147.6 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Change in Cash high stood at $147.6 million for Q2 2025, and its period low was -$80.7 million during Q3 2025.
  • In the last 5 years, Abeona Therapeutics' Change in Cash had a median value of $1.5 million in 2023 and averaged $3.7 million.
  • Data for Abeona Therapeutics' Change in Cash shows a peak YoY increase of 99177.99% (in 2024) and a maximum YoY decrease of 113595.51% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Change in Cash stood at -$5.9 million in 2021, then soared by 158.78% to $3.5 million in 2022, then surged by 180.17% to $9.8 million in 2023, then decreased by 21.82% to $7.6 million in 2024, then plummeted by 1156.89% to -$80.7 million in 2025.
  • Its Change in Cash stands at -$80.7 million for Q3 2025, versus $147.6 million for Q2 2025 and -$7.4 million for Q1 2025.